Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer

Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Herceptin, trastuzumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news